8-Prenylnaringenin from hop (Humulus lupulus L.) – a panacea for menopause?

Summary 8-Prenylnaryngenin (8-PN) is the strongest known phytoestrogen (PE). Its main source is the female inflorescences of hops (Humulus lupulus L.). 8-PN, which, in contrast to other PEs, is proven to have stronger activity and higher affinity for the α subtype of estrogen receptor (ER). Therefore, it may be an effective substitute for hormone replacement therapy (HRT). The studies in postmenopausal women have shown its particular effectiveness in reducing hot flashes. However, a strong stimulation of uterus by 8-PN may be associated with the occurrence of adverse effects (eg. bleeding) and increase the risk of carcinogenesis. The H. lupulus extracts preparations are currently supplements which makes control of the doses used and thus increases the occurrence of uncontrolled self-treatment difficult. This paper presents the current knowledge on 8-PN and discusses the potential risks associated with use of hops to alleviate the symptoms of menopause.

Download Full-text

Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

Geburtshilfe und Frauenheilkunde ◽

10.1055/a-1390-4353 ◽

2021 ◽

Vol 81 (05) ◽

pp. 549-554

Author(s):

Marina Sourouni ◽

Ludwig Kiesel

Keyword(s):

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Current Knowledge ◽

Hormone Replacement ◽

Oncological Treatment ◽

Oncological Safety ◽

Risks And Benefits ◽

Gynaecological Malignancy ◽

Gynaecological Malignancies ◽

Broad Overview

AbstractRapid advances in oncology have led to an increased survival rate in cancer patients, who live long enough to reach the natural age of menopause or experience the end of gonadal function as a side effect of oncological treatment. Survivors after gynaecological malignancies are a major challenge as these diseases are hormone-dependent and hormone replacement therapy (HRT) possibly increases the risk of recurrence. This article is based on a selective literature search for relevant studies and guidelines regarding HRT after gynaecological malignancies and provides a broad overview of current research. The data for assessing the oncological safety of HRT after gynaecological malignancy are insufficient overall. According to current knowledge, HRT is fundamentally contraindicated after breast and endometrial cancer. After ovarian cancer, HRT can be used after assessment of the risks and benefits, while there is usually no contraindication to HRT after vulvar, vaginal or cervical cancer.

Download Full-text

Common Estrogen Receptor Polymorphism Augments Effects of Hormone Replacement Therapy on E-Selectin but Not C-Reactive Protein

Circulation ◽

10.1161/01.cir.0000016173.98826.88 ◽

2002 ◽

Vol 105 (16) ◽

pp. 1879-1882 ◽

Cited By ~ 233

Author(s):

David M. Herrington ◽

Timothy D. Howard ◽

K. Bridget Brosnihan ◽

Donald P. McDonnell ◽

Xiaolin Li ◽

...

Keyword(s):

Estrogen Receptor ◽

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Hormone Replacement ◽

C Reactive Protein ◽

Reactive Protein ◽

Receptor Polymorphism

Download Full-text

Nonassociation of Estrogen Receptor Genotypes with Bone Mineral Density and Estrogen Responsiveness to Hormone Replacement Therapy in Korean Postmenopausal Women

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem.82.4.3879 ◽

1997 ◽

Vol 82 (4) ◽

pp. 991-995 ◽

Cited By ~ 65

Author(s):

Ki Ok Han ◽

In Gul Moon ◽

Young Soon Kang ◽

Ho Yeon Chung ◽

Hun Ki Min ◽

...

Keyword(s):

Bone Mineral Density ◽

Estrogen Receptor ◽

Hormone Replacement Therapy ◽

Lumbar Spine ◽

Replacement Therapy ◽

Postmenopausal Women ◽

Gene Locus ◽

Restriction Site ◽

Hormone Replacement ◽

Mineral Density

Abstract Hormone replacement therapy (HRT) prevents bone loss in postmenopausal women, but some women are resistant to therapy. A recently reported case of severe estrogen resistance caused by a germ-line mutation at the estrogen receptor (ER) gene locus suggests the possibility that other variants of the ER gene could be responsible for resistance to HRT and could also be an answer to the heritable components of bone density. Three restriction fragment length polymorphisms (RFLPs) at the ER gene locus, represented as BstUI (or B variant), PvuII, and XbaI, and their relationship to bone mineral density (BMD) and estrogen responsiveness to HRT were examined in 248 healthy postmenopausal women, aged 41–68 yr (mean± sd, 52.0 ± 4.6 yr) in Korea. The BstUI restriction site was not found in Korean women. The distribution of the PvuII and XbaI RFLPs was as follows: PP, 35 (14.1%); Pp, 136 (54.8%); pp, 77 (31.1%); and XX, 18 (7.3%); Xx, 72 (29.0%); and xx, 158 (63.7%), respectively (capital letters signify the absence of and lower case letters signify the presence of the restriction site of each RFLP). There was no significant relation between ER genotypes and z score values of lumbar spine BMD. Also, no significant genotypic differences were found in the change in lumbar spine BMD and those in biochemical markers before and after 1 yr of HRT. These data indicate no significant effects of ER genotypes on BMD and estrogen responsiveness after HRT.

Download Full-text